Mural Oncology plc [NASDAQ: MURA] stock went on an upward path that rose over 133.98% on Tuesday, amounting to a one-week price increase of more than 121.10%.
Over the last 12 months, MURA stock dropped by -42.89%. The one-year Mural Oncology plc stock forecast points to a potential upside of 65.86. The average equity rating for MURA stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $41.53 million, with 17.10 million shares outstanding and 15.34 million shares in the current float. Compared to the average trading volume of 271.51K shares, MURA stock reached a trading volume of 258842067 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Mural Oncology plc [MURA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MURA shares is $7.06 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MURA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Mural Oncology plc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 25, 2025. The new note on the price target was released on March 25, 2025, representing the official price target for Mural Oncology plc stock. Previously, the target price had yet another raise to $15, while Rodman & Renshaw analysts kept a Buy rating on MURA stock.
The Average True Range (ATR) for Mural Oncology plc is set at 0.37 The Price to Book ratio for the last quarter was 0.29, with the Price to Cash per share for the same quarter was set at 8.38.
MURA Stock Performance Analysis:
Mural Oncology plc [MURA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 121.10. With this latest performance, MURA shares dropped by -40.79% in over the last four-week period, additionally sinking by -30.35% over the last 6 months – not to mention a drop of -42.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MURA stock in for the last two-week period is set at 55.77, with the RSI for the last a single of trading hit 67.38, and the three-weeks RSI is set at 50.02 for Mural Oncology plc [MURA]. The present Moving Average for the last 50 days of trading for this stock 3.0800, while it was recorded at 1.3200 for the last single week of trading, and 3.3500 for the last 200 days.
Insight into Mural Oncology plc Fundamentals:
Mural Oncology plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.83 and a Current Ratio set at 5.83.
MURA Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MURA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mural Oncology plc go to 31.66%.
Mural Oncology plc [MURA] Institutonal Ownership Details
There are presently around $60.57%, or 61.57%% of MURA stock, in the hands of institutional investors. The top three institutional holders of MURA stocks are: ARMISTICE CAPITAL, LLC with ownership of 1.69 million shares, which is approximately 9.9735%. SOLAS CAPITAL MANAGEMENT, LLC, holding 1.27 million shares of the stock with an approximate value of $$3.98 million in MURA stocks shares; and SOLAS CAPITAL MANAGEMENT, LLC, currently with $$2.33 million in MURA stock with ownership which is approximately 4.3929%.
